Clinical Research Directory
Browse clinical research sites, groups, and studies.
ctDNA for Risk Stratification in Melanoma
Sponsor: Herlev and Gentofte Hospital
Summary
This study examines circulating tumor DNA (ctDNA) as a biomarker in patients with primary melanoma, prior to surgical excision. The hypothesis is that ctDNA may be detectable in pre-operative blood samples from patients with high-risk primary melanoma, potentially providing a baseline measurement for future disease monitoring.
Official title: The Value of Circulating Tumour DNA in Risk Stratification in Melanoma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
296
Start Date
2021-09-10
Completion Date
2026-05-03
Last Updated
2026-04-15
Healthy Volunteers
No
Conditions
Locations (1)
Dept. of Plastic and Reconstructive Surgery, Herlev and Gentofte University Hospital
Herlev, Denmark